

# ProFound

Powered by  iCAD

Creating a world where  
Cancer Can't Hide.

## ProFound AI<sup>®</sup> Breast Health Suite



Breast cancer has finally met its match.



# Quality healthcare, reimagined.

## Together, we can change more lives.

Backed by clinical evidence, proven outcomes, and thousands of users worldwide, our AI breast health solutions help detect subtle, early suspicious lesions, and provide precise density and risk insights. ProFound AI delivers unmatched accuracy, multi-vendor compatibility, and workflow advantages, empowering earlier cancer detection and transforming women's lives.



## ProFound Breast Health Suite



**Cancer Detection<sup>1</sup>**



**Density Assessment<sup>1</sup>**



**Risk Evaluation<sup>2</sup>**



**BAC Assessment<sup>3</sup>**

## Real World Clinical Results

**23%** relative increase in cancer detection rate without increasing the rate of recalls.<sup>8</sup>

**8M+** mammograms read each year.

## A partner you can count on.



**20+ Years of Experience in Breast AI**

Headquarters: Nashua, NH, USA



**Globally Diverse Algorithm<sup>10</sup>**

100+ contributing facilities



**CE Marked and FDA Cleared: ProFound AI**

First DBT AI FDA Cleared in December 2018




# Experience the ProFound AI difference.


## Cancer Detection

Concurrent-read detection solution for 2D and 3D mammography that rapidly detects malignant soft tissue densities and calcifications with unrivaled accuracy and industry-leading AUC performance.

- 2x** Performance compared to other AI platforms.<sup>5</sup>
- 8%** Improvement in sensitivity.<sup>4</sup>
- 7%** Reduction in recall rate.<sup>4</sup>
- 52%** Reduction in reading time.<sup>4</sup>



## Density Assessment



High Breast Density Rating

Consider Supplemental Screening<sup>9</sup> (e.g. ABUS / MRI)


### Standardization matters.

Provide an objective and consistent BI-RADS breast density assessment, seamlessly integrated into existing workflows.

Unique two-part algorithm assesses the **dispersion** and localized **concentration** of breast density.

## Risk Evaluation

- 1<sup>st</sup>** Image-based, one- or two-year risk assessment tool. Identifies high risk of developing breast based only on a 2D or 3D mammogram.<sup>2</sup>
- 2.4x** More accurate compared to traditional lifetime models.<sup>6,7</sup>



## Meet the ProFound Scorecard.

Automated, integrated, and easy to read. The ProFound Scorecard provides an actionable mammographic case summary.

Provides the information needed to personalize patient care.

### Critical Insights at a Glance.

- Color-coded Overall Case Score.
- Automated Density Assessment Score.
- Personalized 1-2 year Risk Score.<sup>2</sup>
- Worklist Prioritization by Case Scores.\*

Patient Name:  
Patient ID:  
Patient DOB/Age:  
Accession #:  
Study Date:


ProFound Breast Health Suite  
ProFound AI® Scorecard

#### ProFound AI Detection Case Score



62

#### PowerLook Density Assessment



C<sup>+</sup>

#### ProFound AI Risk: DBT Absolute Risk 1-Year



H 0.65%

Flexible turnkey deployment.



ProFound Cloud



ProFound On-Premises

Visit [iCADmed.com](https://www.icadmed.com) to request a demo



1. FDA Cleared. CE Marked. Health Canada Licensed. 2. ProFound AI Risk is CE Marked and Health Canada Licensed. ProFound AI Risk is not available in all geographies. 3. BACA is not available in all geographies. 4. Conant EF, et al. Radiology: Artificial Intelligence 2019. 5. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>. Accessed 1-20-23. FDA 510K submissions K182373 (iCAD), K201019 (Hologic) and K193229 (ScreenPoint). 6. Mikael Eriksson et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Sci. Transl. Med. 14, eabn3971 (2022). DOI: 10.1126/scitranslmed.abn3971. 7. Eriksson M, Czene K, Strand F, Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D, Hall P. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020 Nov;297(2):327-333. doi: 10.1148/radiol.2020201620. Epub 2020 Sep 8. PMID: 32897160. 8. Schilling, K. Presented Research at ECR 2023; Vienna, Austria. 9. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-914. doi: 10.1016/j.jacr.2023.04.002. Epub 2023 May 5. PMID: 37150275 10. Data collected from nine countries worldwide. Internal data on file proprietary information of iCAD, Inc.

Disclaimer: Images may vary based on regulatory clearance and/or configuration.